With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback
Just a few weeks after Novartis $NVS spelled out exactly why it believes RTH258 can carve out a blockbuster chunk of Regeneron’s AMD market for Eylea, its big rival says that a next-gen combo won’t be riding to their rescue.
Early Monday Regeneron $REGN said both Phase II studies of nesvacumab — an angiopoietin2 (Ang2) antibody — in combination with Eylea failed to beat a solo version of their flagship therapy. And that’s forcing both Regeneron and its allies at Bayer — which paid $50 million upfront to partner here — to drop Phase III plans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
